Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: J Thromb Haemost. 2020 Mar 5;18(5):1183–1196. doi: 10.1111/jth.14748

Figure 6: PDK1 regulates Bcl-3 protein synthesis and clot-retraction in activated platelets.

Figure 6:

A. Washed human platelets were untreated or pretreated with the PDK1 inhibitor BX-795 (1μM) for 5 min, followed by stimulation with 2-methylthio-ADP (2MeSADP) (50nM) under stirring. Western blots were then probed for total Bcl-3 protein. Beta actin was used as loading control. The western blots shown are representative of three independent experiments. Graphs represent mean ± standard error of the mean from at least three different experiments (****P < 0.05). B. Washed wild type (WT) or PDK1 knockout (PDK1−/−) murine platelets were stimulated with 2-methylthio-ADP (2MeSADP) (50nM) under stirring for 5 min. Western blots were then probed total Bcl-3. The western blots shown are representative of three independent experiments. Graphs represent mean ± standard error of the mean from at least three different experiments (****P < 0.05). C. Washed human platelets were incubated with BX-795 for 5 min prior to initiating clot retraction as described in methods. Photographs were taken at the times indicated. Data are representative of three independent experiments.